| Literature DB >> 30202219 |
Hadel Abo El-Enin1,2, Areej Hamed Al-Shanbari3.
Abstract
PURPOSE: Development of a new dosage-form of antiepileptic-drugs appropriated for children.Entities:
Keywords: Antiepileptic; CNS, Central Nervous System; Cl, Clonazepam; Clonazepam; Cubogels; Cubosomes; Cubs, cubosomes; EE, entrapping efficiency; Epilepsy; Et, ethanol; GMO, glycerol-mono-oleate; I.P, Intraperitoneal injections; PBS, phosphate buffer saline; PCS, peripheral cholinergic signs; PDI, polydispersity index; PF127, Poloxamer 407; PS, particle size; PVA, polyvinyl alcohol; SMS, stereotyped movements signs; TDDS, Transdermal Drug Delivery System
Year: 2018 PMID: 30202219 PMCID: PMC6128721 DOI: 10.1016/j.jsps.2018.04.004
Source DB: PubMed Journal: Saudi Pharm J ISSN: 1319-0164 Impact factor: 4.330
The composition of different Cl cubosome formulae.
| F | 5%(w/w) GMO/PF127 | %Stabilizer | ||
|---|---|---|---|---|
| GMO | PF127 | PVA | Ethanol | |
| CA | 97.5 | 2.5 | 0 | – |
| C2 | 95 | 2.5 | 2.5 | – |
| C3 | 92.5 | 2.5 | 5 | – |
| C4 | 95 | 5 | 0 | – |
| C5 | 92.5 | 5 | 2.5 | – |
| C6 | 90 | 5 | 5 | – |
| C7 | 90 | 10 | 0 | – |
| C8 | 87.5 | 10 | 2.5 | – |
| C9 | 85 | 10 | 5 | – |
| C10 | 95 | 2.5 | – | 2.5 |
| C11 | 92.5 | 2.5 | – | 5 |
| C12 | 92.5 | 5 | – | 2.5 |
| C13 | 90 | 5 | – | 5 |
| C14 | 87.5 | 10 | – | 2.5 |
| C15 | 85 | 10 | – | 5 |
Notes: The drug is solubilized in the organic phase.
All formulae contain; 0.25% (w/w) clonazepam 95% (w/w) water.
The GMO/PF127 concentration is constant 5%w/w of the total Cubosome weight.
The stabilizer concentration is (w/w) percentage form the disperse phase.
The Composition of the prepared clonazepam Cubosomes Cl-Cu formulae and the measured parameter (n = 3).
| F | Response | PDI | |
|---|---|---|---|
| PS (nm) | EE% | ||
| CA | 1089 ± 1.01 | 9.54 ± 1.95 | 1.67 ± 0.02 |
| C2 | 485 ± 2.12 | 25.87 ± 1.95 | 0.32 ± 0.01 |
| C3 | 358 ± 2.84 | 45.98 ± 2.63 | 0.45 ± 0.05 |
| C4 | 378-±3.21 | 11.85 ± 1.57 | 0.45 ± 0.01 |
| C5 | 352 ± 1.91 | 51.08 ± 3.82 | 0.39 ± 00.05 |
| C6 | 215.3 ± 2.85 | 68.97 ± 4.57 | 0.58 ± 0.02 |
| C7 | 686 ± 4.12 | 21.58 ± 2.99 | 0.63 ± 0.03 |
| C8 | 251 ± 2.09 | 65.87 ± 4.58 | 0.66 ± 0.04 |
| C9 | 361 ± 3.11 | 74.25 ± 5.21 | 0.44 ± 0.01 |
| C10 | 512 ± 4.12 | 24.56 ± 2.01 | 0.85 ± 0.04 |
| C11 | 364 ± 3.78 | 34.51 ± 2.91 | 0.79 ± 0.05 |
| C12 | 297 ± 2.17 | 49.54 ± 2.99 | 0.68 ± 0.02 |
| C13 | 264 ± 2.16 | 69.21 ± 3.98 | 0.43 ± 0.01 |
| C14 | 384 ± 3.06 | 64.45 ± 5.29 | 0.58 ± 0.02 |
| C15 | 375 ± 3.45 | 73.98 ± 5.35 | 0.38 ± 0.01 |
Fig. 1Response surface plot for the effect of stabilizer and Pluronic F127 (B) concentration on (A) the particle size (PS) and (B) the entrapping efficiency (EE).
Fig. 2Size distribution of Cl-Cubosome (A) C6 and (B) C13. Transmission electron micrographs of the selected Cubosome at magnification of 100,000. (C) C6 and (D) C13.
Fig. 3(A) Cumulative percentage of Cl release profiles from the selected cubosomal formula in comparison with the drug (Cl) in phosphate buffer (pH 7) for 4 h. (B) Cumulative percentage of Cl release profiles from cubogels in phosphate buffer pH 7.4 (n = 3).
Cubosomes particle sizes during the 10-days stress test stability study.
| Formulation | Time (days) | High light beam (4500 ± 500 L×) | Temperature (up to 60 °C) | ||
|---|---|---|---|---|---|
| Diameter (nm) | PDI | Diameter (nm) | PDI | ||
| C6 | 0 | 252 | 0.58 | 252 | 0.58 |
| 5 | 252.6 | 0.55 | 255 | 0.59 | |
| 10 | 253.8 | 0.57 | 254 | 0.56 | |
| C13 | 0 | 264 | 0.43 | 264 | 0.43 |
| 5 | 263.4 | 0.44 | 267 | 0.42 | |
| 10 | 265.6 | 0.45 | 269 | 0.42 | |
Fig. 4Rheological characteristics of the prepared cubosomal gel formulae.
Rheological properties of prepared cubogels.
| Formula | Flow index (n) | Regression coefficient (r2) Type of flow | Flow type | ||
|---|---|---|---|---|---|
| Bingham | Casson | Carreau | |||
| G6 | 0.3736 | 0.767 | 0.6158 | 0.9987 | Shear thinning pseudoplastic |
| G13 | 0.3321 | 0.8669 | 0.8307 | 0.9911 | Shear thinning pseudoplastic |
Fig. 5(A) Cumulative percentage of Cl permeated from the selected formulae through rabbit skin over 48 h at 32 °C ± 0.5 compared to its aqueous suspension. (B) Amount of Cl deposited from the selected formulae in the rabbit skin.
Transdermal permeation parameters of Cl-cubosomal formulae through a rabbit skin compared to the pure drug aqueous suspension.
| Experiment | J* (mg/cm2 h) | Kpa** (cm/h) × 10−2 | Enhancement factor |
|---|---|---|---|
| Pure drug | 0.554777 | 27.73885 | – |
| C13 | 3.3568 | 167.84 | 6.050719 |
| G13 | 2.347165 | 117.3582 | 4.230825 |
J* = transdermal flux value; Kpa** = the permeability coefficient.
Behavioural changes in the animals in pilocarpine model of seizures.
| Group | % PCS | % SMS | Seizures latency | % Seizures | SE latency | Death latency | % Death |
|---|---|---|---|---|---|---|---|
| −ve group | 100 | 96.4 | 6.56 ± 0.66 | 96.4 | 13.18 ± 1.48 | 17.0 ± 1.71 | 82 |
| C-CL | 100 | 95.9 | 6.16 ± 0.63 | 95.9 | 13.33 ± 1.23 | 17.8 ± 1.68 | 81 |
| R-CL | 99.9 | 77.1 | 21.71 ± 2.34 | 40 | 24.71 ± 2.15 | 24.17 ± 2.23 | 68 |
| T-CL | 99.7 | 46.7 | 33.17 ± 3.33 | 17.5 | 47.17 ± 3.21 | 51.25 ± 4.13 | 25 |
SE = status epileptics; −ve group = pilocarpine 400 mg/kg, IP, n = 15; C-CL = GMOPF127 mixture, t.d., n = 15; R-CL = Clonazepam of 100 mg/g, 40 mg/kg, orally, n = 15; T-CL = CL-cubogel of 50 mg/g, 40 mg/kg, t.d., n = 15. The results were expressed as the mean ± standard error and percentage (%).